Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses exciting updates in Waldenström’s macroglobulinemia (WM), drawing focus on the value of covalent and non-covalent BTK inhibitors, and further comments on the importance of genomic research in WM. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.